Journal article

Improving glycaemic control in children and adolescents: Which aspects of therapy really matter?

TC Skinner, FJ Cameron

Diabetic Medicine | Published : 2010

Abstract

In paediatric diabetes, the concept of intensive therapy in the post-Diabetes Control and Complications Trial period has become subverted by a pharmaco-technological paradigm at the expense of other aspects of care such as goal-setting and psychosocial support. This review examines which patients benefit most from intensive therapy in terms of glycaemic control (HbA 1c). It also reviews published controlled trial and observational data relating to the impact of various insulin types and delivery systems on glycaemic control and canvasses the literature dealing with the impact of patient support, philosophy of care, goal setting and treating team dynamic on HbA1c. Taking into account the char..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

TCS has consulted to and FJC is a member of the Hvidoere International Study Group on Childhood Diabetes, which is supported by Novo Nordisk. FJC has received research funding support, travel support and honoraria from the following diabetes-related companies: Novo Nordisk, Eli Lilly, Aventis, Medtronic, Abbott and Animas.